Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis

A composition, tuberculosis technology, applied in the field of biomedicine, can solve the problem of not finding a drug composition, etc., and achieve the effect of shortening the treatment time, low recurrence rate, and low adverse reaction rate

Inactive Publication Date: 2021-02-02
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main reason is that no suitable pharmaceutical composition has been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis
  • Pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis
  • Pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1, be applicable to the composition of the pharmaceutical composition that treats newly diagnosed smear-positive pulmonary tuberculosis by 4.5 months chemotherapy regimen

[0031] The pharmaceutical composition provided by the present invention that is applicable to the treatment of newly diagnosed smear-positive pulmonary tuberculosis by 4.5 months chemotherapy regimen consists of levofloxacin, isoniazid, rifampicin, pyrazinamide and ethambutol, according to the unit dose (single day) Dosage) for packaging, specifically as follows (1) or (2):

[0032] (1) The pharmaceutical composition of the unit dose (single daily dose) contains 1 part of levofloxacin with a specification of 600 mg, 1 part of isoniazid with a specification of 300 mg, 1 part of rifampicin with a specification of 450 mg, and 3 parts of pyridoxine with a specification of 500 mg. Azinamide and 1 serving of ethambutol in a strength of 750 mg. It is suitable for newly diagnosed smear-positive p...

Embodiment 2

[0034] The specific application of pharmaceutical composition in embodiment 2, embodiment 1

[0035] 1. Subject population

[0036] 1. Conditions for using this program

[0037] (1) Sign the informed consent;

[0038] (2) Age 18-65;

[0039] (3) The sputum smear is positive twice or the culture is positive, and the chest X-ray shows that there are active tuberculosis lesions in the lungs;

[0040] (4) Never received anti-tuberculosis treatment or anti-tuberculosis treatment for less than 1 month;

[0041] (5) Relevant laboratory examinations shall be carried out before enrollment. Among them, ALT and total bilirubin were less than 2 times the upper limit of normal value. Creatinine clearance greater than 30ml / s / min. HB is greater than 7.0 g / dL. Platelets greater than 50×10 9 / L;

[0042] (6) Women of childbearing age have a negative urine pregnancy test and promise to take contraceptive measures during the course.

[0043] 2. Exclusions

[0044] (1) Combined with se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis. The invention provides the pharmaceutical composition for treating primary treatment of smeared-positive pulmonary tuberculosis. The pharmaceutical composition is composed of levofloxacin, isoniazid, rifampicin, pyrazinamide and ethambutol. The pharmaceutical composition provided by the invention can be used for completing the primary treatment of the smeared-positive pulmonary tuberculosis through chemotherapy for four and a half months with a shorter range and higher efficiency, and compared with a standard six-month chemotherapy regimen, the pharmaceutical composition has the characteristic of high focus absorptivity, under the condition of ensuring a higher sputum culture negative conversion rate, a lower adverse reaction rate, a higher cure rate and a lower recurrence rate. According to the present invention, the treatment time of the primary treatment of the smeared-positive pulmonary tuberculosis can be shortened, and the pharmaceutical composition has important significance for reducing the prevalence and propagation oftuberculosis.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a pharmaceutical composition suitable for ultra-short-course treatment of primary smear-positive pulmonary tuberculosis. Background technique [0002] Tuberculosis remains the most serious public health problem threatening people's health worldwide. According to the global report on tuberculosis released by the World Health Organization (WHO) in 2019, there were about 10 million new cases of tuberculosis in the world in 2018, with an incidence rate of 1.30 / 100,000. In 2018, there were 1.451 million deaths from tuberculosis. The number of tuberculosis cases in China is 866,000, accounting for 9% of the world, ranking second. Currently, the course of chemotherapy for newly diagnosed sensitive pulmonary tuberculosis is 6 to 9 months. Studies have shown that the longer the course of tuberculosis treatment, the higher the rate of irregular medication. In addition to reducing the cure ra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5383A61K31/4409A61K31/496A61K31/4965A61K31/133A61P31/06A61P11/00
CPCA61K31/5383A61K31/4409A61K31/496A61K31/4965A61K31/133A61P31/06A61P11/00A61K2300/00
Inventor 唐神结李亮高孟秋杜建刘荣梅刘宇红高静韬马丽萍
Owner BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com